A n D GUID eLIneS affordability may often dictate which medications may be prescribed.
Patients who have exhausted prescription drug coverage or who are uninsured may require …

The P2Y 12 receptor is a key player in platelet activation and represents an effective
pharmacological target for the inhibition of platelet aggregation and prevention of …

Antiplatelet therapy is used in the treatment of patients with acute coronary syndromes,
stroke, and those undergoing percutaneous coronary intervention. Clopidogrel is the most …

Background Ticagrelor inhibits the equilibrative-nucleoside-transporter-1 and thereby,
adenosine cell re-uptake. Ticagrelor limits infarct size (IS) in non-diabetic rats and the effect …

Objective To compare hemorrhagic events between clopidogrel and ticagrelor in the Platelet
Inhibition and Patient Outcomes (PLATO) trial. Methods We examined the FDA Medical …

Objectives: The study sought to compare the clinical efficacy and safety of P2Y12 inhibitors
in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary …

Atorvastatin and ticagrelor combination is a widely accepted therapy for secondary
prevention of ischaemic heart disease. However, rhabdomyolysis is a well‐known rare side …

Introduction: Aspirin, clopidogrel, prasugrel and ticagrelor are antiplatelet agents for the
prevention of ischemic events in patients with acute coronary syndromes (ACS) …

Objective: Unusual clinical course Background: Following acute coronary intervention in
cardiology patients, the combined medical therapy with the platelet inhibitory drug ticagrelor …

Objective Ascertain platelet inhibition and patient outcomes (PLATO) trial conduct. Methods
We examined information from the FDA complete response review. Results FDA Medical …